683 Capital Management, LLC Fibrogen Inc Transaction History

683 Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $3,827 - $14,613	-11,598 Reduced 0.54%	2,138,402 $855,000
Q2 2024 Aug 14, 2024	BUY	$0.89 - $2.36 $267,000 - $708,000	300,000 Added 16.22%	2,150,000 $1.91 Million
Q1 2024 May 15, 2024	BUY	$0.73 - $2.73 $839,314 - $3.14 Million	1,149,746 Added 164.19%	1,850,000 $4.35 Million
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.91 $266,096 - $637,231	700,254 New	700,254 $623,000

34.6M

461K

102K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $28.1M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.